“As the Global Fund [to Fight AIDS, Tuberculosis and Malaria] turns 10 on January 26, 2012, Nigerian families should join in the celebration of this innovative initiative that has saved the lives of millions here in Nigeria and across the globe,” Bello Bissalla, project manager for private sector and government partnerships at Friends of the Global Fund Africa, writes in Nigeria’s BusinessDay. “Much of the Global Fund’s success could be attributed to its performance-based financing mechanism, which creates room for transparency in the purchase, distribution and administration of drugs for these three diseases,” Bissalla continues, noting the grant review process “ensures that grant recipients show verified evidence of performance before receiving the next tranche of funding, thus ensuring transparency and implementation of the grant according to the plan.”
“As the World Economic Forum kicks off this week in Davos, Switzerland, the importance of global health — and the health of the globe — is getting special attention,” Karl Hofmann, president and CEO of Population Services International (PSI), writes in this post in The Hill’s “Congress Blog.” He continues, “The world’s still massive bottom of the economic pyramid — some 2-3 billion people — represents a potential $5 trillion in purchasing power,” but without access to “quality health care and services, … their global economic impact suffers. Imagine if by simple investments in health, we turned these struggling individuals and families into healthy, active consumers and producers.”
This post in the U.N. Foundation’s “Shot@Life” blog examines how Honduras, “one of the poorest countries in the Western hemisphere,” has achieved “one of the highest vaccination coverage rates in the world, averaging close to 99 percent.” The blog writes, “We wanted to see firsthand how Honduras has achieved such amazing results, so last week Shot@Life traveled there with a U.S. Congressional staff delegation to learn more about their extremely effective immunization programs” and details the vaccination efforts of the rural town La CaÃ±ada (Willingham, 1/23).
In this Washington Post “Davos Diary” blog entry, Kate Roberts, vice president of corporate marketing, communications and advocacy at PSI, writes about what to expect at the World Economic Forum, beginning on January 25 in Davos, Switzerland. Noting that poor health and access to health care can prevent a growing middle-class population from reaching its “full economic potential,” Roberts writes, “The key to changing this scenario will be finding ways to encourage this emerging class of consumers to adopt healthier behaviors, and giving them the means to do so.” She says public-private partnerships are critical to solving these issues.
“Thirty years after AIDS made its deadly debut, a future without the disease is finally within reach,” a Boston Globe editorial states, adding, “But just as science is on the verge of winning the battle, financial resources and political will are flagging.” The editorial details reductions in HIV spending, a Congressional stipulation that U.S. funds cannot be spent on needle-exchange programs, and new science showing how HIV treatment can help people living with the disease live longer and reduce the risk of them spreading the virus.
“The astounding thing about the global abortion debate is not that some people have deeply held views about what a pregnancy is and when a human existence begins” but that “policymakers continue to ignore carefully amassed information about the actual outcome of programs and laws related to sexuality and reproduction,” Marianne MÃ¸llmann, senior policy adviser with Amnesty International’s International Secretariat, writes in this Guardian opinion piece. MÃ¸llmann cites an analysis by the U.S.-based Guttmacher Institute, published in the Lancet last week, which she says has two main conclusions: “first, when governments fail to provide contraception for those who want it, abortion figures stay the same; and second, where abortion is illegal, the procedure is predominantly unsafe.”
The WHO is expected to hold a meeting in February to discuss controversy over recent research on the H5N1 bird flu virus, after the U.S. National Scientific Advisory Board for Biosecurity (NSABB) in December advised the journals Science and Nature to withhold publishing two teams’ research on the virus for fear the information could “fall into the wrong hands,” a commentary in the Economist’s “Babbage” blog states. “In a statement sent to Science, the WHO says that research” into bird flu genetics is “an important tool for global surveillance efforts,” the commentary says.
In this post in Global Health Frontline News’ “Notes From the Field” blog, Kevin Cain, chief of the tuberculosis (TB) branch for a research and public health collaboration between the Kenya Medical Research Institute (KEMRI) and the CDC in Kisumu, Kenya, reports on TB research underway as part of the collaboration. Cain highlights several current research initiatives in Kisumu and concludes, “The world cannot afford another phase of neglect. We know by partnering with governments as well as affected communities in innovative ways more progress can be made improving programs and the tools available for diagnosing, treating, and preventing TB, and lives will be saved” (1/20).
This post in the Foreign Policy Association blog discusses reports from earlier this month of “an emerging strain of ‘totally drug-resistant’ tuberculosis (TDR-TB)” in India, which the Indian government last week denied, “arguing that the 12 cases were in fact extensively drug resistant (XDR).” The blog states, “Whether or not it’s fair to use the TDR moniker, drug resistance is a serious, emerging issue that may very well define the next stage of global health,” concluding, “We are reaching a turning point, one at which some drug resistant pathogens are on the cusp of shifting from a handful of cases, an endemic, to a bigger, epidemic or even pandemic problem. Now is the time to initiate discussions on what the global community will do to stem drug resistance” (Robinson, 1/21).
A funding shortfall led the Global Fund to Fight AIDS, Tuberculosis and Malaria to announce in November that “it won’t make any grants to fund programs for at least two years,” a Deseret News editorial notes and calls on the U.S. to take a leadership position in saving the fund. The editorial states, “Few worldwide initiatives have the success record of the Global Fund …, but those breakthroughs may not have much chance to save many lives,” and notes that the non-profit lobbying group “Results is calling for the Obama administration to assemble an emergency meeting of donor nations this spring to find ways to ensure that the fund and its programs are able to continue and to provide new medicines where they are needed most.”